[Leish-l] RES: testing vaccinated dogs for immunopotentiation
Patrick Bastien
patrick.bastien at univ-montp1.fr
Sat Oct 15 05:12:38 BRT 2011
Dear KP,
That's it for article [3].
(don't ask me how I got this proof, I cant' remember).
Best wishes
P. Bastien
Professeur Patrick Bastien
Laboratoire de Parasitologie-Mycologie, Faculté de Médecine
UMR MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1)
Centre National de Référence des Leishmania
CHU de Montpellier
39 Avenue Charles Flahault
34295 Montpellier Cedex 5, France
"Chang, Kwang-Poo" <KwangPoo.Chang at rosalindfranklin.edu> a écrit :
> I also recall the description of sexual transmission in human
> leishmaniasis in old literature, but this is rare.
>
>
> Going back to the issue of congenital transmission in human and
> canine leishmaiasis, I listed 3 articles below from a pubmed search.
>
> [1] Pediatrics. 1999 Nov;104(5):e65.
> Congenital transmission of visceral leishmaniasis (Kala Azar) from
> an asymptomatic mother to her child.
> Meinecke CK, Schottelius J, Oskam L, Fleischer B.
> SourceChildren's Hospital of Stuttgart (Olgahospital), Stuttgart, Germany.
>
>
>
> [2] J Parasitol. 2005 Aug;91(4):970-2.
> Transplacental transmission of a North American isolate of
> Leishmania infantum in an experimentally infected beagle.
> Rosypal AC, Troy GC, Zajac AM, Frank G, Lindsay DS.
> SourceDepartment of Biomedical Sciences and Pathobiology,
> Virginia-Maryland Regional College of Veterinary Medicine, Virginia
> Tech, Blacksburg, Virginia 24061, USA
>
> [3] Vet Parasitol. 2009 Dec 3;166(1-2):159-62. Epub 2009 Aug 15.
> First report of vertical transmission of Leishmania (Leishmania)
> infantum in a naturally infected bitch from Brazil.
> da Silva SM, Ribeiro VM, Ribeiro RR, Tafuri WL, Melo MN, Michalick MS.
> SourceDepartamento de Parasitologia, Instituto de Ciências
> Biológicas, Universidade Federal de Minas Gerais, 31270-901 Belo
> Horizonte, MG, Brazil.
>
> I hope Dr. Rosypal and the authors of article [3] could make the pdf
> reprints of their articles available, since they were published in
> journals, which are not readily available.
>
>
>
> KP
>
> -----Original Message-----
> From: leish-l-bounces at lineu.icb.usp.br
> [mailto:leish-l-bounces at lineu.icb.usp.br] On Behalf Of Christopher
> Peacock
> Sent: Sunday, October 09, 2011 10:33 PM
> To: leish-l at lineu.icb.usp.br
> Subject: Re: [Leish-l] RES: testing vaccinated dogs for immunopotentiation
>
> Hi,
> There is also this rather bizarre story of a Gulf War veteran who
> returned with leishmaniasis, this link is a Veterans association
> website and suggest both sexual transmission and vertical
> transmission. Not sure how reliable this information is but it does
> seem to be contested in court. Would be interesting to know more
> details on this case and whether it has any evidence to support the
> cases, as far as I am aware there has only been one suggested case
> of sexually transmitted Leishmania in humans documented many years
> ago.
>
> http://www.vawatchdog.org/07/nf07/nfJUN07/nf062907-3.htm
>
> http://www.leishmaniasis.us/Leish.html
>
> Cheers
>
> Chris
>
> Associate Professor Christopher Peacock
> Discipline of Microbiology & Immunology M502
> School of Biomedical, Biomolecular & Chemical Sciences
> The University of Western Australia
> Nedlands WA 6009
>
> ph 00 61(0)8 9287 6172
> fax 00 61(0)8 9346 2912
>
> -----Original Message-----
> From: leish-l-bounces at lineu.icb.usp.br
> [mailto:leish-l-bounces at lineu.icb.usp.br] On Behalf Of Patrick Bastien
> Sent: Saturday, 8 October 2011 1:31 AM
> To: leish-l at lineu.icb.usp.br
> Subject: Re: [Leish-l] RES: testing vaccinated dogs for immunopotentiation
>
> There were several earlier reports of this vertical transmission, even
> in the US: among others,
> Rosypal AC, J.Parasitol. 2005, 970-972 and 113-115
> Magno da Silva, Vet Parasitol 2009
> Pangrazio, Vet Parasitol 2009
>
> Best regards
> P. Bastien
>
> Professeur Patrick Bastien
> Laboratoire de Parasitologie-Mycologie, Faculté de Médecine
> UMR MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1)
> Centre National de Référence des Leishmania
> CHU de Montpellier
> 39 Avenue Charles Flahault
> 34295 Montpellier Cedex 5, France
>
> "Chang, Kwang-Poo" <KwangPoo.Chang at rosalindfranklin.edu> a écrit :
>
>> What Jenni said indicates that transplacental transmission of canine
>> leishmaniasis has some implication in considering dog vaccination.
>>
>>
>>
>> Of further interest is the question of whether this transplacental
>> transmission could also occur in other reservoir animals or even in
>> human leishmaniasis ? I recall the description of such transmission in
>> human cases in some very early literature, but that has been always
>> considered as unlikely or extremely rare, more as a hypothesis than
>> reality. This issue may have been addressed in more recent
>> epidemiological studies of VL familial clustering in well-established
>> endemic sites ? Congenital transmission might escape our attention,
>> should the outcome be largely asymptomatic ?
>>
>>
>>
>> KP
>>
>>
>>
>> ________________________________
>>
>> From: Jennie Blackwell [mailto:jmb37 at cam.ac.uk]
>> Sent: Wednesday, October 05, 2011 6:46 PM
>> To: Chang, Kwang-Poo
>> Cc: Petersen, Christine A [V PTH]; TECSA - Luiz Ristow; John David;
>> leish-l at lineu.icb.usp.br
>> Subject: Re: [Leish-l] RES: testing vaccinated dogs for
>> immunopotentiation
>>
>>
>>
>> I doubt it. Treatment might but if the mum was already infected and
>> passed the parasite to the foetus I don't see how a vaccine would work
>> to clear the parasite from the foetus!
>>
>>
>>
>> Slightly different question as to whether vaccinating mums will give
>> them sufficient protection to not pass the parasite to the pup in utero
>> should they get infected themselves after vaccination.
>>
>>
>>
>> Cheers all, Jennie
>>
>> Jenefer M. Blackwell
>>
>> TICHR, CCHR, UWA
>>
>> Phone: +61 8 94897910
>>
>> From my iPhone
>>
>>
>> On 29 Sep 2011, at 00:36, "Chang, Kwang-Poo"
>> <KwangPoo.Chang at rosalindfranklin.edu> wrote:
>>
>> Of interest is the question of whether vaccination would clear
>> the infection of the pub, which has congenitally inherited L infantum ?
>>
>>
>>
>> KP
>>
>>
>>
>>
>> ________________________________
>>
>>
>> From: Petersen, Christine A [V PTH] [mailto:kalicat at iastate.edu]
>>
>> Sent: Wednesday, September 28, 2011 11:23 AM
>> To: Chang, Kwang-Poo; TECSA - Luiz Ristow; John David
>> Cc: leish-l at lineu.icb.usp.br; Petersen, Christine A [V PTH]
>> Subject: RE: [Leish-l] RES: testing vaccinated dogs for
>> immunopotentiation
>>
>>
>>
>> The reference for this article is:
>> <http://www.ncbi.nlm.nih.gov/pubmed/21532741>
>> http://www.ncbi.nlm.nih.gov/pubmed/21532741
>>
>> As it was published in a PLoS journal its free access to all.
>>
>> Based on our studies and recent ones from Brazil, I do believe
>> that to remove Leish from the canine reservoir, transmission from mom to
>> pup will need to be addressed.
>>
>> Christy Petersen
>>
>>
>>
>> From: Chang, Kwang-Poo
>> [mailto:KwangPoo.Chang at rosalindfranklin.edu]
>> Sent: Wednesday, September 28, 2011 10:20 AM
>> To: TECSA - Luiz Ristow; John David
>> Cc: leish-l at lineu.icb.usp.br; Petersen, Christine A [V PTH]
>> Subject: RE: [Leish-l] RES: testing vaccinated dogs for
>> immunopotentiation
>>
>>
>>
>> Christine Petersen published an article about transplacental
>> transmission of L infantum in the USA canine leishmaniasis. I just
>> wonder about the implication of this finding in considering vaccination
>> against the disease transmitted this way ?
>>
>>
>>
>> KP
>>
>>
>>
>>
>> ________________________________
>>
>>
>> From: <mailto:leish-l-bounces at lineu.icb.usp.br>
>> leish-l-bounces at lineu.icb.usp.br
>> [mailto:leish-l-bounces at lineu.icb.usp.br]
>> <mailto:%5bmailto:leish-l-bounces at lineu.icb.usp.br%5d> On Behalf Of
>> TECSA - Luiz Ristow
>> Sent: Wednesday, September 28, 2011 9:08 AM
>> To: 'John David'
>> Cc: <mailto:leish-l at lineu.icb.usp.br> leish-l at lineu.icb.usp.br
>> Subject: [Leish-l] RES: testing vaccinated dogs for
>> immunopotentiation
>>
>>
>>
>> Hi !
>>
>>
>>
>> There are these papers about
>>
>> These need a very critical reading to discuss
>>
>> This discussion with all about the matter and these papers is
>> very welcome! (at least for me!)
>>
>> Regards for all
>>
>> Luiz Ristow
>>
>>
>>
>> <image001.gif>
>>
>>
>>
>> De: <mailto:leish-l-bounces at lineu.icb.usp.br>
>> leish-l-bounces at lineu.icb.usp.br
>> [mailto:leish-l-bounces at lineu.icb.usp.br]
>> <mailto:%5bmailto:leish-l-bounces at lineu.icb.usp.br%5d> Em nome de John
>> David
>> Enviada em: segunda-feira, 26 de setembro de 2011 18:44
>> Para: Dr GR Rajasekariah
>> Cc: <mailto:leish-l at lineu.icb.usp.br> leish-l at lineu.icb.usp.br;
>> Carlos Gouvea; hubert mazure; <mailto:smithyman at cellabs.com.au>
>> smithyman at cellabs.com.au
>> Assunto: Re: [Leish-l] testing vaccinated dogs for
>> immunopotentiation
>>
>>
>>
>> I think that for any vaccine developed to protect dogs against
>> VL, but which is also meant to prevent transmission of VL to humans, the
>> developers should show that after the vaccinated dog has been challenged
>> with Leishmania, it does not transmit Leishmania to sand flies.
>>
>> John R David, M.D.
>>
>> Richard Pearson Strong Professor Emeritus
>>
>> Department of Immunology and Infectious Diseases
>>
>> Harvard School of Public Health
>>
>> Professor of Medicine, Harvard Medical School
>>
>> 300 W. 23rd Street, Apt. 13K
>>
>> New York, NY, 10011
>>
>> Tel: 212 414 8646
>>
>> Email: <mailto:jdavid at hsph.harvard.edu> jdavid at hsph.harvard.edu
>>
>>
>>
>>
>>
>> On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:
>>
>>
>>
>> Hello EveryOne,
>> I am responding to the topic on European VL Dog vaccine.
>> It is a great challenge in devising a protective vaccine
>> against visceral leishmaniasis in dogs. This point equally applies the
>> same challenge for human situation.
>> Because Th-2 response is so dominant during VL infection,
>> modulating Th-2 into Th-1 response is a big challenge to immunologists.
>>
>> Key points lies in the presentation of appropriate antigen in
>> appropriate dose to stimulate the Th-1 dependent protective immune
>> response.
>> I understand several vaccines are in the market and real
>> efficacy of these vaccines will come out once introduced to field
>> conditions.
>>
>> I just wanted to inform you that we have a suitable antibody kit
>> for testing the immunopotentiation in dogs following vaccination of
>> dogs.
>> Our assay is based on the released promastigote antigens.
>> It is a highly sensitive assay.
>> Currently we supply reagents for determination of total IgG
>> antibodies in serum.
>> If any particular group is interested then we are able to
>> provide appropriate reagent for detection of specific IgG2 and other
>> isotype specific antibody detection.
>> Because our antibody detection ELISA is based on the
>> exo-antigens such an ELISA would be of exceptional type for measuring
>> antibody response in vaccinated animals.
>> Highly suitable for diagnosing dogs responded to vaccines.
>>
>> Recently I came to know that some of commercial kits were found
>> to be not useful for detecting seroconversion in dogs vaccinated with
>> FML vaccine (Leish-Immune) in Brazil.
>> Because we use released antigens in our kit, any such problems
>> will overcome if they use Canine Leish IgG CELISA (Manufacturer Cellabs
>> Pty Ltd Brookvale NSW Australia email <mailto:sales at cellabs.com.au>
>> sales at cellabs.com.au).
>> If any one is interested to know more about our antibody
>> detection ELISA based on exo-antigens please contact us.
>>
>> This is for your kind information.
>>
>> Dr GR Rajasekariah
>> Sydney
>> Australia
>> <mailto:raj at cellabs.com.au> raj at cellabs.com.au
>>
>>
>>
>>
>>
>>
>> ----- Original Message ----- From: <
>> <mailto:leish-l-request at lineu.icb.usp.br>
>> leish-l-request at lineu.icb.usp.br>
>> To: < <mailto:leish-l at lineu.icb.usp.br>
>> leish-l at lineu.icb.usp.br>
>> Sent: Wednesday, August 10, 2011 5:18 PM
>> Subject: Leish-l Digest, Vol 44, Issue 3
>>
>> Send Leish-l mailing list submissions to
>>
>> <mailto:leish-l at lineu.icb.usp.br>
>> leish-l at lineu.icb.usp.br
>>
>>
>>
>> To subscribe or unsubscribe via the World Wide Web,
>> visit
>>
>>
>> <http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l>
>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>>
>> or, via email, send a message with subject or body
>> 'help' to
>>
>> <mailto:leish-l-request at lineu.icb.usp.br>
>> leish-l-request at lineu.icb.usp.br
>>
>>
>>
>> You can reach the person managing the list at
>>
>> <mailto:leish-l-owner at lineu.icb.usp.br>
>> leish-l-owner at lineu.icb.usp.br
>>
>>
>>
>> When replying, please edit your Subject line so it is
>> more specific
>>
>> than "Re: Contents of Leish-l digest..."
>>
>>
>>
>>
>>
>> Today's Topics:
>>
>>
>>
>> 1. European VL Dog Vaccine - CaniLeish?: (jeffrey shaw)
>>
>> 2. Re: FW: Leishmaniasis Pathology Network (Moazzem
>> Hossain)
>>
>> 3. Re: FW: Leishmaniasis Pathology Network (Moazzem
>> Hossain)
>>
>>
>>
>>
>>
>>
>> ----------------------------------------------------------------------
>>
>>
>>
>> Message: 1
>>
>> Date: Tue, 9 Aug 2011 15:18:44 +0000
>>
>> From: jeffrey shaw < <mailto:jayusp at hotmail.com>
>> jayusp at hotmail.com>
>>
>> Subject: [Leish-l] European VL Dog Vaccine - CaniLeish?:
>>
>> To: Leish-L < <mailto:leish-l at lineu.icb.usp.br>
>> leish-l at lineu.icb.usp.br>
>>
>> Message-ID: <
>> <mailto:COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>
>> COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>
>>
>> Content-Type: text/plain; charset="windows-1252"
>>
>>
>>
>>
>>
>> CaniLeish?:
>>
>> The European Commission granted a marketing
>> authorisation valid throughout the European Union, for CaniLeish to
>> Virbac S.A. on 14/03/2011.
>>
>> This vaccine, CaniLeish?, will initially be launched in
>> Portugal at the end of the first half of 2011. This will be followed
>> rapidly by launches in other countries in the endemic area: Spain,
>> France, Greece and Italy (not in chronological order). This roll-out
>> takes account of the geographical prevalence of the disease and the time
>> required to build vaccine production up to full capacity. The launch in
>> Northern European countries from where there is a flow of summer
>> visitors to the endemic area will be part of a second phase.
>>
>> The basis of this vaccine are excreted proteins plus a
>> saponin adjuvant purified from Quil-A. Its efficacy was determined in a
>> 2 year open field trial.
>>
>> The vaccine is given to dogs as three injections,
>> three weeks apart, under the skin. The first injection can be given from
>> six months of age, the second injection is given three weeks later and
>> the third three weeks from the second one. Afterward a single ?booster?
>> should be given every year to maintain protection.
>>
>> -------------- next part --------------
>>
>> An HTML attachment was scrubbed...
>>
>> URL: <
>> <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e
>> /attachment-0001.htm>
>> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e/
>> attachment-0001.htm>
>>
>>
>>
>> ------------------------------
>>
>>
>>
>> Message: 2
>>
>> Date: Wed, 10 Aug 2011 13:07:17 +0600
>>
>> From: Moazzem Hossain < <mailto:directordcbd at gmail.com>
>> directordcbd at gmail.com>
>>
>> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology
>> Network
>>
>> To: jeffrey shaw < <mailto:jayusp at hotmail.com>
>> jayusp at hotmail.com>, "Prof. Paul Kaye"
>>
>> < <mailto:paul.kaye at york.ac.uk> paul.kaye at york.ac.uk>
>>
>> Cc: "Prof. Dr. Moazzem Hossain" <
>> <mailto:profdrmoazzemhossain at gmail.com> profdrmoazzemhossain at gmail.com>,
>>
>> Leish-L < <mailto:leish-l at lineu.icb.usp.br>
>> leish-l at lineu.icb.usp.br>
>>
>> Message-ID:
>>
>> <
>> <mailto:CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.c
>> om> CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.com>
>>
>> Content-Type: text/plain; charset=windows-1252
>>
>>
>>
>> 10 Aug 2011
>>
>>
>>
>> Dear Professor Paul Kaye,
>>
>>
>>
>> Thank you for your email. Please find attached our
>> supportive letter
>>
>> of interest for Leishmaniasis Pathology Network.
>>
>> Looking forward for your kind response.
>>
>>
>>
>> Best regards.
>>
>>
>>
>>
>>
>> --
>>
>> *Prof. Dr. Moazzem Hossain *
>>
>> Ex - Director Disease Control
>>
>> Ministry of Health & Family Welfare
>>
>> Government of Bangladesh
>>
>> *Mailing address*:
>>
>> Founder Chairman and Project Director
>>
>> Institute of Allergy & Clinical Immunology of Bangladesh
>> (IACIB)
>>
>> Room 4 - 5 (2nd Floor), Green Super Market, Green Road
>>
>> Dhaka -1205, Bangladesh.
>>
>> Phone:880-2-8115646 (O )
>>
>> 880-1715038551(Mobile)
>>
>> Email: <mailto:directordcbd at gmail.com>
>> directordcbd at gmail.com
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>> On 8/9/11, jeffrey shaw < <mailto:jayusp at hotmail.com>
>> jayusp at hotmail.com> wrote:
>>
>>
>>
>>
>>
>>
>>
>> Date: Tue, 9 Aug 2011 11:58:52 +0100
>>
>> From: <mailto:paul.kaye at york.ac.uk>
>> paul.kaye at york.ac.uk
>>
>>
>>
>> Subject: Leishmaniasis Pathology Network
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>> Dear all,
>>
>> Invitation to participate in a global
>> pathology
>>
>> network for
>>
>> research and training in leishmaniasis
>> (LeishPathNet)
>>
>> You may recall the Dormy House meeting in
>> 2008
>>
>> and some of
>>
>> the plans we put forward? Over
>>
>> the past
>>
>> couple years, I have also spoken more to a
>> few of you about one
>>
>> idea that was
>>
>> formulated at Dormy, namely of setting up a
>> digital pathology
>>
>> network. I have
>>
>> also had numerous discussions with the
>> major equipment
>>
>> manufacturers to see if
>>
>> any of them would be supportive of helping
>> us to develop such an
>>
>> initiative. There have
>>
>> been two major
>>
>> develoments recently. First,
>>
>> Carl Zeiss
>>
>> is willing to work with us to set up an
>> integrated global digital
>>
>> pathology
>>
>> network (providing a significant financial
>> and technical
>>
>> contribution) and
>>
>> second, the Wellcome Trust is willing to
>> review a pre-proposal to
>>
>> fund the
>>
>> initiative through their new Biomedical
>> Resources Grant scheme
>>
>> (
>> <http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/St
>> rategic-awards-and-initiatives/wtdv031727.htm>
>> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Str
>> ategic-awards-and-initiatives/wtdv031727.htm)
>>
>> .
>>
>> I have attached an outline of the project
>> that
>>
>> I had sent to
>>
>> the Trust for their initial views, which I
>> think is reasonably
>>
>> self-explanatory.
>>
>> They appeared very
>>
>> enthusiastic! The main
>>
>> question now is whether enough of
>>
>> you are still supportive? [ I will also be
>> sending this email to
>>
>> others, but please feel free to circulate ]
>>
>>
>>
>>
>>
>> I think the
>>
>> project will be
>>
>> challenging, but success could have a
>> real impact on the way we
>>
>> conduct
>>
>> business. It should serve not only as a
>> vehicle to enhance
>>
>> research in
>>
>> leishmaniasis, but the model would be
>> equally applicable across
>>
>> a broad range
>>
>> of diseases and global challenges (with
>> leishmaniasis setting
>>
>> the pace).
>>
>> If we wish to
>>
>> proceed, the requirements
>>
>> are that we submit a pre-proposal to the
>> Trust by Oct 18th 2011.
>>
>> This pre-proposal is short (4 sections of
>> 350 words) and
>>
>> requires
>>
>> letters of support from the community.
>>
>> If you are
>>
>> supportive of the idea that
>>
>> we try to take this forward (and there is
>> plenty of scope for
>>
>> later iteration
>>
>> of the detail), I would be grateful if
>> you could please provide
>>
>> me with a
>>
>> letter of support by September
>>
>> 12th
>>
>> 2011, indicating whether you would like
>> to be a network
>>
>> partner if the bid
>>
>> is successful. You could
>>
>> also be
>>
>> supportive but not wish to become
>> directly involved at this
>>
>> stage, and such
>>
>> letters are equally valuable. Your letter
>> might also stress the
>>
>> added value
>>
>> that the network could provide, its
>> importance for research and
>>
>> training and/or
>>
>> for progressing the translational agenda.
>>
>> It would also be an opportunity to
>> indicate whether your
>>
>> group (or
>>
>> institute, if multiple groups) would be
>> interested in bidding to
>>
>> be one of the
>>
>> initial ?designated laboratories?.
>>
>> If there is
>>
>> sufficient support to
>>
>> proceed and if subsequently the
>> pre-proposal is successful (we
>>
>> will know on 22nd
>>
>> Nov), then I will need a few volunteers
>> to help finalise the
>>
>> full proposal,
>>
>> which will be due on Jan 26th 2012.
>>
>> A funding decision will be made on May
>> 26th
>>
>> 2012.
>>
>> Best wishes
>>
>> and of course I am happy to
>>
>> discuss any points further (though I will
>> be out of the UK from
>>
>> Aug 10 ?Sept
>>
>> 12)
>>
>> Paul
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>> --
>>
>> Professor Paul Kaye, Ph.D., FRCPath.
>>
>> Deputy Dean (Research), Hull York Medical
>> School, and
>>
>> Director, Centre for Immunology and Infection
>>
>> Department of Biology and Hull York Medical
>> School
>>
>> University of York
>>
>> Wentworth Way
>>
>> York YO10 5YW
>>
>> United Kingdom
>>
>>
>>
>> Tel: +44 (0)1904 328840
>>
>> Fax: +44 (0)1904 328844
>>
>> Email: <mailto:paul.kaye at york.ac.uk>
>> paul.kaye at york.ac.uk < <mailto:paul.kaye at york.ac.uk>
>> mailto:paul.kaye at york.ac.uk>
>>
>>
>>
>> Centre Administrator and PA: Elizabeth Greensted
>>
>> Tel: 01904 328845
>>
>> Email: <mailto:liz.greensted at york.ac.uk>
>> liz.greensted at york.ac.uk < <mailto:liz.greensted at york.ac.uk>
>> mailto:liz.greensted at york.ac.uk>
>>
>>
>>
>> Centre Email: <mailto:cii at york.ac.uk>
>> cii at york.ac.uk < <mailto:cii at york.ac.uk> mailto:cii at york.ac.uk>
>>
>>
>>
>> Centre website: <http://www.york.ac.uk/cii>
>> http://www.york.ac.uk/cii
>>
>>
>>
>> Times Higher Education University of the Year
>> 2010
>>
>>
>>
>> Email disclaimer:
>> <http://www.york.ac.uk/docs/disclaimer/email.htm>
>> http://www.york.ac.uk/docs/disclaimer/email.htm
>>
>>
>>
>>
>>
>>
>>
>>
>>
>> ------------------------------
>>
>>
>>
>> Message: 3
>>
>> Date: Wed, 10 Aug 2011 13:06:47 +0600
>>
>> From: Moazzem Hossain < <mailto:directordcbd at gmail.com>
>> directordcbd at gmail.com>
>>
>> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology
>> Network
>>
>> To: jeffrey shaw < <mailto:jayusp at hotmail.com>
>> jayusp at hotmail.com>, "Prof. Paul Kaye"
>>
>> < <mailto:paul.kaye at york.ac.uk> paul.kaye at york.ac.uk>
>>
>> Cc: "Prof. Dr. Moazzem Hossain" <
>> <mailto:profdrmoazzemhossain at gmail.com> profdrmoazzemhossain at gmail.com>,
>>
>> Leish-L < <mailto:leish-l at lineu.icb.usp.br>
>> leish-l at lineu.icb.usp.br>
>>
>> Message-ID:
>>
>> <
>> <mailto:CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.c
>> om> CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.com>
>>
>> Content-Type: text/plain; charset="windows-1252"
>>
>>
>>
>> 10 Aug 2011
>>
>>
>>
>> Dear Professor Paul Kaye,
>>
>>
>>
>> Thank you for your email. Please find attached our
>> supportive letter
>>
>> of interest for Leishmaniasis Pathology Network.
>>
>> Looking forward for your kind response.
>>
>>
>>
>> Best regards.
>>
>>
>>
>>
>>
>> --
>>
>> *Prof. Dr. Moazzem Hossain *
>>
>> Ex - Director Disease Control
>>
>> Ministry of Health & Family Welfare
>>
>> Government of Bangladesh
>>
>> *Mailing address*:
>>
>> Founder Chairman and Project Director
>>
>> Institute of Allergy & Clinical Immunology of Bangladesh
>> (IACIB)
>>
>> Room 4 - 5 (2nd Floor), Green Super Market, Green Road
>>
>> Dhaka -1205, Bangladesh.
>>
>> Phone:880-2-8115646 (O )
>>
>> 880-1715038551(Mobile)
>>
>> Email: <mailto:directordcbd at gmail.com>
>> directordcbd at gmail.com
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>> On 8/9/11, jeffrey shaw < <mailto:jayusp at hotmail.com>
>> jayusp at hotmail.com> wrote:
>>
>>
>>
>>
>>
>>
>>
>> Date: Tue, 9 Aug 2011 11:58:52 +0100
>>
>> From: <mailto:paul.kaye at york.ac.uk>
>> paul.kaye at york.ac.uk
>>
>>
>>
>> Subject: Leishmaniasis Pathology Network
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>> Dear all,
>>
>> Invitation to participate in a global
>> pathology
>>
>> network for
>>
>> research and training in leishmaniasis
>> (LeishPathNet)
>>
>> You may recall the Dormy House meeting in
>> 2008
>>
>> and some of
>>
>> the plans we put forward? Over
>>
>> the past
>>
>> couple years, I have also spoken more to a
>> few of you about one
>>
>> idea that was
>>
>> formulated at Dormy, namely of setting up a
>> digital pathology
>>
>> network. I have
>>
>> also had numerous discussions with the
>> major equipment
>>
>> manufacturers to see if
>>
>> any of them would be supportive of helping
>> us to develop such an
>>
>> initiative. There have
>>
>> been two major
>>
>> develoments recently. First,
>>
>> Carl Zeiss
>>
>> is willing to work with us to set up an
>> integrated global digital
>>
>> pathology
>>
>> network (providing a significant financial
>> and technical
>>
>> contribution) and
>>
>> second, the Wellcome Trust is willing to
>> review a pre-proposal to
>>
>> fund the
>>
>> initiative through their new Biomedical
>> Resources Grant scheme
>>
>> (
>> <http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/St
>> rategic-awards-and-initiatives/wtdv031727.htm>
>> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Str
>> ategic-awards-and-initiatives/wtdv031727.htm)
>>
>> .
>>
>> I have attached an outline of the project
>> that
>>
>> I had sent to
>>
>> the Trust for their initial views, which I
>> think is reasonably
>>
>> self-explanatory.
>>
>> They appeared very
>>
>> enthusiastic! The main
>>
>> question now is whether enough of
>>
>> you are still supportive? [ I will also be
>> sending this email to
>>
>> others, but please feel free to circulate ]
>>
>>
>>
>>
>>
>> I think the
>>
>> project will be
>>
>> challenging, but success could have a
>> real impact on the way we
>>
>> conduct
>>
>> business. It should serve not only as a
>> vehicle to enhance
>>
>> research in
>>
>> leishmaniasis, but the model would be
>> equally applicable across
>>
>> a broad range
>>
>> of diseases and global challenges (with
>> leishmaniasis setting
>>
>> the pace).
>>
>> If we wish to
>>
>> proceed, the requirements
>>
>> are that we submit a pre-proposal to the
>> Trust by Oct 18th 2011.
>>
>> This pre-proposal is short (4 sections of
>> 350 words) and
>>
>> requires
>>
>> letters of support from the community.
>>
>> If you are
>>
>> supportive of the idea that
>>
>> we try to take this forward (and there is
>> plenty of scope for
>>
>> later iteration
>>
>> of the detail), I would be grateful if
>> you could please provide
>>
>> me with a
>>
>> letter of support by September
>>
>> 12th
>>
>> 2011, indicating whether you would like
>> to be a network
>>
>> partner if the bid
>>
>> is successful. You could
>>
>> also be
>>
>> supportive but not wish to become
>> directly involved at this
>>
>> stage, and such
>>
>> letters are equally valuable. Your letter
>> might also stress the
>>
>> added value
>>
>> that the network could provide, its
>> importance for research and
>>
>> training and/or
>>
>> for progressing the translational agenda.
>>
>> It would also be an opportunity to
>> indicate whether your
>>
>> group (or
>>
>> institute, if multiple groups) would be
>> interested in bidding to
>>
>> be one of the
>>
>> initial ?designated laboratories?.
>>
>> If there is
>>
>> sufficient support to
>>
>> proceed and if subsequently the
>> pre-proposal is successful (we
>>
>> will know on 22nd
>>
>> Nov), then I will need a few volunteers
>> to help finalise the
>>
>> full proposal,
>>
>> which will be due on Jan 26th 2012.
>>
>> A funding decision will be made on May
>> 26th
>>
>> 2012.
>>
>> Best wishes
>>
>> and of course I am happy to
>>
>> discuss any points further (though I will
>> be out of the UK from
>>
>> Aug 10 ?Sept
>>
>> 12)
>>
>> Paul
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>>
>> --
>>
>> Professor Paul Kaye, Ph.D., FRCPath.
>>
>> Deputy Dean (Research), Hull York Medical
>> School, and
>>
>> Director, Centre for Immunology and Infection
>>
>> Department of Biology and Hull York Medical
>> School
>>
>> University of York
>>
>> Wentworth Way
>>
>> York YO10 5YW
>>
>> United Kingdom
>>
>>
>>
>> Tel: +44 (0)1904 328840
>>
>> Fax: +44 (0)1904 328844
>>
>> Email: <mailto:paul.kaye at york.ac.uk>
>> paul.kaye at york.ac.uk < <mailto:paul.kaye at york.ac.uk>
>> mailto:paul.kaye at york.ac.uk>
>>
>>
>>
>> Centre Administrator and PA: Elizabeth Greensted
>>
>> Tel: 01904 328845
>>
>> Email: <mailto:liz.greensted at york.ac.uk>
>> liz.greensted at york.ac.uk < <mailto:liz.greensted at york.ac.uk>
>> mailto:liz.greensted at york.ac.uk>
>>
>>
>>
>> Centre Email: <mailto:cii at york.ac.uk>
>> cii at york.ac.uk < <mailto:cii at york.ac.uk> mailto:cii at york.ac.uk>
>>
>>
>>
>> Centre website: <http://www.york.ac.uk/cii>
>> http://www.york.ac.uk/cii
>>
>>
>>
>> Times Higher Education University of the Year
>> 2010
>>
>>
>>
>> Email disclaimer:
>> <http://www.york.ac.uk/docs/disclaimer/email.htm>
>> http://www.york.ac.uk/docs/disclaimer/email.htm
>>
>>
>>
>>
>>
>> -------------- next part --------------
>>
>> A non-text attachment was scrubbed...
>>
>> Name: Letter Leish UK.doc
>>
>> Type: application/msword
>>
>> Size: 46080 bytes
>>
>> Desc: not available
>>
>> URL: <
>> <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a
>> /attachment.doc>
>> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a/
>> attachment.doc>
>>
>>
>>
>> ------------------------------
>>
>>
>>
>> _______________________________________________
>>
>> Leish-l mailing list
>>
>> <mailto:Leish-l at lineu.icb.usp.br>
>> Leish-l at lineu.icb.usp.br
>>
>>
>> <http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l>
>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>>
>>
>>
>>
>>
>> End of Leish-l Digest, Vol 44, Issue 3
>>
>> **************************************
>>
>>
>>
>>
>>
>>
>> =======
>> Email scanned by PC Tools - No viruses or spyware found.
>> (Email Guard: 7.0.0.26, Virus/Spyware Database: 6.18330)
>> <http://www.pctools.com/> http://www.pctools.com/
>> =======
>> _______________________________________________
>> Leish-l mailing list
>> <mailto:Leish-l at lineu.icb.usp.br> Leish-l at lineu.icb.usp.br
>> <http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l>
>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>>
>>
>>
>>
>>
>> _______________________________________________
>> Leish-l mailing list
>> Leish-l at lineu.icb.usp.br
>> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>>
>>
>
>
>
>
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
> --
> This message has been scanned for viruses and
> dangerous content by MailScanner, and is
> believed to be clean.
>
> #####################################################################################
> This e-mail message has been scanned for Viruses and Content and cleared
> by MailMarshal
> #####################################################################################
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
>
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: Vertical transmission of leish in bitch_daSillva_VetParasit2009.pdf
Type: application/pdf
Size: 516257 bytes
Desc: not available
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20111015/3fff7c78/attachment-0001.pdf>
More information about the Leish-l
mailing list